Protagonist Therapeutics Inc.

A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants? – News Opener

Pfizer Inc.’s PFE, +0.71% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it’s approved by…

Read More »